Advancing Neurotherapeutics. Transforming Lives.
NeuroSigma is a bioelectronic medical device company leveraging non-invasive trigeminal-nerve stimulation to treat chronic neurological disorders.
0
FDA Cleared Device
0
Clinical Trials
20
Patents Issued
0
+
Patients Safely Treated
NeuroSigma converts gentle, external electrical pulses into precisely targeted neuromodulation—without surgery, implants, or medication. Our technology stimulates the trigeminal nerve, a key pathway that influences brain function, mood, and attention.
This work matters:
-
Clinically Validated: Supported by 10 clinical trials and more than 2,500 patient treatments to date.
-
Science-Driven Design: Built on decades of neuroengineering research and protected by 50+ issued patents.
-
Large-Scale Impact: Addresses multi-billion-dollar neurological and neuropsychiatric markets with strong unmet needs including indications that includes autism spectrum disorder (ASD), epilepsy, and depression.
Our goal is clear: to make neuromodulation accessible, evidence-based, and transformative for patients and families worldwide.
The Monarch eTNS® System
The First FDA Cleared Device for Treating Pediatric ADHD.
The Monarch eTNS® System is indicated for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD) as a monotherapy in patients ages 7 through 12 years old who are not currently taking prescription ADHD medications.
The Monarch TNS® is available by prescription only and is intended to be used in the home under the supervision of a caregiver during periods of sleep.
Important Safety Information:
Indication: Monarch eTNS® System is indicated for treatment of pediatric ADHD as a monotherapy in patients ages 7 to 12 who are not currently on prescription ADHD medications. The device is for use during sleep under the supervision of a caregiver.
Contraindications: Not for use in patients with implanted pacemakers, neurostimulators, or metallic/electronic head implants. Do not use in children under 7.
Common side effects: Drowsiness, increased appetite, insomnia, teeth clenching, headache, fatigue. Rx Only. Please refer to the Instructions for Use or contact us for full safety information.”
For full Indication, Contraindications and Important Safety Information see the detailed labeling or contact Medical Affairs at (310) 479-3100.
References:
1. McGough JJ, Loo SK, Sturm A, et al. An eight-week, open-label pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder. Brain Stimulation. 2015;8:299-304.
2. McGough JJ, Sturm A, Cowen J, et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2019;58(4):403-411.